| Literature DB >> 24570768 |
Maryellen Sandor1, Devinder Singh2, Ronald P Silverman2, Hui Xu1, Patrick G De Deyne1.
Abstract
OBJECTIVE: We examined the differences in capsule formation between 2 commercially available human acellular dermal matrices in a nonhuman primate model.Entities:
Keywords: AlloDerm; acellular dermal matrix; animals; breast implants; foreign-body reaction; tissue expanders
Year: 2014 PMID: 24570768 PMCID: PMC3914385
Source DB: PubMed Journal: Eplasty ISSN: 1937-5719
Bilateral placement of TEs in a nonhuman primate model, with or without coverage by HADM
| Animal ID | Placement | Implant condition |
|---|---|---|
| 02703 | Left | TE-only |
| Right | TE + AM | |
| N993 | Left | TE-only |
| Right | TE + AM | |
| 04099 | Left | TE-only |
| Right | TE + AM | |
| 01659 | Left | TE-only |
| Right | TE + AD | |
| 08247 | Left | TE-only |
| Right | TE + AD | |
| 07655 | Left | TE-only |
| Right | TE + AD | |
| 07656 | Left | TE + AM |
| Right | TE + AD | |
| 07654 | Left | TE + AM |
| Right | TE + AD | |
| 07657 | Left | TE + AM |
| Right | TE + AD |
Treatment groups included tissue expander (TE)-only, TE + non–gamma-irradiated human acellular dermal matrix (HADM) (AlloDerm; AD), and TE + gamma-irradiated HADM (AlloMax; AM).
Antibodies used for immunohistochemical detection
| Primary Antibody | Secondary Antibody | ||||||
|---|---|---|---|---|---|---|---|
| Stain | Positive control | Species | Dilution | Supplier | Species | Dilution | Supplier |
| a-SMA | Monkey aorta | Mouse anti-human | 1:60 | Sigma A5691 | Goat anti-mouse | 1:300 | Biorad 170-6516 |
| CD-68 | Monkey lymph node | Mouse anti-human | Pre-dilute | Zymed/Invitrogen 08-0125 | Goat anti-mouse | 1:300 | Biorad 170-6516 |
| MMP-1 | Human ovarian tumor | Rabbit | 1:600 | Fitzgerald 10R-M112a | Rabbit polyclonal | Undiluted | Thermo Shandon TL-060-HL |
| TIMP-1 | Human prostate tumor | Mouse | 1:100 | Fitzgerald 10R-M112b | Rabbit polyclonal | Undiluted | Thermo Shandon TL-060-HL |
| Procollagen -1 | Human skin wound | Rat | 1:600 | Abcam ab64409 | Goat anti-rat | Undiluted | Biocare GHP516 G |
α-SMA indicates alpha-smooth muscle cell actin; CD, clusters of differentiation; MMP-1, matrix metalloproteinase-1; TIMP-1, tissue inhibitor of metalloproteinase-1.
Figure 1Representative histology and immunohistochemical staining using serial sections of tissue overlying the implanted tissue expander (TE) interface (indicated by *) for the TE-only (A-D), AlloMax (AM; E-H), and AlloDerm (AD; I-L) groups. Tissues are stained/labeled for hematoxylin and eosin (A, E, I); CD68 epitope for macrophages (B, F, J); α-smooth muscle cell actin (SMA) for myofibroblasts (C, G, K); and matrix metalloproteinase-1 (MMP-1) for matrix collagenase (D, H, I). In the TE-only group, a rim of macrophages can be detected ([, panel B) and presence of myofibroblasts ([, panel C). Tissue around the AM-covered TE had more modest macrophage presence ([, panel F); however, clusters were observed (indicated by arrowhead in F) and myofibroblast staining was strong ([, panel G). The lowest signal for macrophages and myofibroblast was noted in tissues from AD-covered TE. Excessive MMP-1 staining (D, H, L) is suggestive of accelerated ECM degradation in TE-only and clustered activity in AM (not observed in tissue from AD-covered TE).
Histology/immunohistochemistry observations from tissues overlying the tissue expander for evaluable surgical sites
| Animal/Implant ID | Resorption | Capsule Formation | α-SMA | CD68 | MMP-1 | TIMP-1 | Procollagen-1 |
|---|---|---|---|---|---|---|---|
| TE + AD | |||||||
| 08247R | Absent | Absent | − | +/− | +/− | − | − |
| 01659R | Absent | Absent | − | + | ++ | − | − |
| 07656R | Absent | Absent | − | + | ++ | + | ++ |
| 07654R | Absent | Absent | +/− | + | ++ | +/− | +/− |
| TE + AM | |||||||
| N993R | Present | Present | ++ | +/− | +++ | ++ | ++ |
| 02703R | Present | Absent | − | +++ | ++ | + | + |
| 04099R | Present | Present | + | +++ | +++ | +/− | +/− |
| 07656L | Absent | Present | ++ | ++ | ++ | + | ++ |
| 07657L | Present | Present | ++ | + | +++ | + | ++ |
| 07654L | Present | Present | + | ++ | + | +/− | + |
| TE-only | |||||||
| 08247L | N/A | Present | ++ | + | +++ | + | + |
| 01659L | N/A | Present | ++ | ++ | ++ | ++ | + |
| N993L | N/A | Present | ++ | + | +++ | ++ | + |
| 02703L | N/A | Present | ++ | +++ | +++ | + | +/− |
| 04099L | N/A | Present | ++ | +++ | ++ | + | + |
*Resorption defined by loss of HADM thickness, uniformity of thickness (H&E), and uneven distribution of elastin (VVG).
†Capsule formation defined by multiple layers of collagen comprised linearly arranged fibroblast-like cells at the matrix-TE interface.
‡A single layer of a-SMA myofibroblasts was observed histologically at the matrix/TE interface.
α-SMA indicates alpha-smooth muscle actin; AD, AlloDerm; AM, AlloMax; CD, cluster of differentiation; H&E, hematoxylin and eosin; HADM, human acellular dermal matrix; MMP-1, matrix metalloproteinase-1; TE, tissue expander; TIMP-1, tissue inhibitor of metalloproteinase-1; VVG, Verhoeff-Van Gieson.
In situ cytokine profile
| pg Cytokine/mg Total protein | |||
|---|---|---|---|
| Implant group | IL-6 | INF-γ | TNF-α |
| TE only | 194.49 ± 288.20 | 25.81 ± 16.33 | 20.69 ± 5.78 |
| TE + AD | 16.33 ± 6.68 | 26.02 ± 10.69 | 18.29 ± 2.47 |
| TE + AM | 67.33 ± 53.59 | 16.98 ± 9.92 | 16.64 ± 2.63 |
AD indicates AlloDerm; AM, AlloMax; INF-γ, interferon-γ; IL-6, interleukin 6; TE, tissue expander; TNF-α, tumor necrosis factor-α.
Biomechanical properties of HADMs following 9 weeks subcutaneous implantation enclosing a synthetic tissue expander
| Out-of-package properties, mean (SD) | Postimplantation properties, mean (SD) | |||
|---|---|---|---|---|
| Material | Tensile strength maximum stress, MPa | Elastic modulus, MPa | Tensile strength maximum stress, MPa | Elastic modulus, MPa |
| AD | 10.93 (4.61) | 48.85 (24.43) | 6.00 (2.55) | 20.48 (5.80) |
| AM | 6.19 (0.79) | 17.42 (2.49) | 0.73 (0.46) | 3.51 (3.43) |
AD indicates AlloDerm; AM, AlloMax; HADMs, human acellular dermal matrices.